Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SDCBP | O00560 | 1/20 | 0.44 |
| ▸ | SDC2 | P34741 | 1/20 | 0.44 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | HPN | P05981 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3728033 | 0.87 | DYRK1A (0.47) | NAMPTHDAC1DYRK1ASMN1; SMN2 | |
| SCHEMBL13999418 | 0.84 | DYRK1A (0.49) | NAMPTHDAC1DYRK1AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3378929 | 0.81 | CYP17A1 (0.56) | NAMPTHDAC1HDAC6CYP17A1 | |
| SCHEMBL506891 | 0.80 | CYP17A1 (0.61) | NAMPTHDAC1DYRK1AL3MBTL1CYP17A1 | |
| SCHEMBL20299920 | 0.80 | DYRK1A (0.56) | NAMPTHDAC1DYRK1A | |
| SCHEMBL2568479 | 0.80 | NAMPT (0.66) | NAMPTHDAC1L3MBTL1CYP17A1AKT1 | |
| SCHEMBL29376317 | 0.80 | DYRK1A (0.56) | NAMPTHDAC1DYRK1A | |
| SCHEMBL81094 | 0.80 | FPR3 (0.58) | NAMPTHDAC1L3MBTL1SMN1; SMN2FPR3 | |
| SCHEMBL3671026 | 0.79 | CYP1A2 (0.41) | HDAC1CYP17A1SMN1; SMN2 | |
| SCHEMBL3180689 | 0.78 | L3MBTL1 (0.61) | NAMPTHDAC1L3MBTL1HDAC6SDCBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | NAMPT 3303/4885HDAC1 3723/4885DYRK1A 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.